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Abstract
This paper summarizes the Part 2 of the proceedings of the 8th International Conference on Management and
Rehabilitation of Chronic Respiratory Failure, held in Pescara, Italy, on 7 and 8 May, 2015. It summarizes the
contributions from numerous experts in the field of chronic respiratory disease and chronic respiratory failure. The
outline follows the temporal sequence of presentations.
This paper (Part 2) includes sections regarding: Promoting Physical Activity across the Spectrum of COPD (Physical
activity: definitions, measurements, and significance; Increasing Physical Activity through Pharmacotherapy in
COPD); Pulmonary Rehabilitation in Critical Illness (Complex COPD with comorbidities and its impact during acute
exacerbation; Collaborative Self-Management in COPD: A Double-Edged Sword?; and Pulmonary Rehabilitation in
Critical Illness.
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Background
This paper summarizes the Part 2 of the proceedings of
the 8th International Conference on Management and Re-
habilitation of Chronic Respiratory Failure, held in Pescara,
Italy on 7 and 8 May, 2015. It summarizes the contribu-
tions from numerous experts in the field of chronic re-
spiratory disease and chronic respiratory failure. The
outline follows the temporal sequence of presentations.
Promoting physical activity across the spectrum
of COPD
Rationale
Physical activity is commonly reduced in the COPD pa-
tient, regardless of disease severity. This physical
inactivity is a predictor of poor outcome. This sympo-
sium will define the problem of physical inactivity in the
COPD patient and propose ways to reduce its impact.
Physical activity: definitions, measurements, and
significance (Alfredo Chetta)
Key points:
Physical activity:
 Physical activity can be defined as any bodily
movement produced by skeletal muscles that results
in energy expenditure
 Physical activity is reduced in COPD, but is weakly
correlated with other measures of disease severity
 Physical activity is further reduced during the COPD
exacerbation
 Inactivity strongly predicts mortality in COPD* Correspondence: RZuWalla@stfranciscare.org13Pulmonary and Critical Care, St Francis Hospital, Hartford, CT 06106, USA
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 Physical activity, which can be objectively measured,
is becoming a key outcome measure in COPD
Definitions
Physical activity is defined as “any bodily movement pro-
duced by skeletal muscles that results in energy expend-
iture beyond resting energy expenditure” [1]. Physical
activity is distinguished from exercise capacity. The lat-
ter is defined as “physical activities that are specifically
performed with the intention of improving physical fit-
ness” [2]. Regular physical activity is crucial to guarantee a
healthy lifestyle and, to this end, the World Health
Organization guidelines for physical activity have recently
recommended that all subjects should do 150 min of
moderate-intensity physical activity per week [3].
Measurements
Physical activity can be assessed by different techniques,
such as behavioral observation, specifically designed
questionnaires, measurement of energy expenditure dur-
ing bodily movement, heart rate monitoring, and motion
sensors. Behavioral observation is a time-consuming and
intrusive method, and therefore, is not feasible for the
assessment of physical activity in large populations. Spe-
cifically designed questionnaires are subjective measures
commonly used to estimate daily physical activities.
However, these can incorrectly estimate physical activity
levels in patients with chronic obstructive pulmonary
disease (COPD) [4].
Energy expenditure due to physical activity can be reli-
ably assessed by indirect calorimetry, more specifically
by means of the doubly labeled water (DLW) method
[5]. Noteworthy, DLW is time consuming and expensive,
and should be restricted as a gold standard for the valid-
ation of field methods of assessing physical activity [6].
Heart rate monitoring is an objective physiological
marker for the assessment of physical activity. However,
in order to be considered an effective measurement, in-
dividual calibration is required coupling heart rate with
oxygen uptake. Heart rate monitoring is commonly used
in combination with body movement as a measure of
physical fitness [6].
Motion sensors, such as pedometers and accelerome-
ters, are the most promising tools for the assessment of
physical activity. Pedometers are step counters, which,
compared to the accelerometers and indirect calorimetry,
underestimate the energy expenditure in slow-moving
COPD patients [7]. Accelerometers are electronic devices,
which can provide a reliable estimate of physical activity
outcomes, such as body posture, quantity and intensity of
body movements, energy expenditure, and physical activ-
ity level [8]. More specifically, accelerometers can detect
body movement along one, two or three axes. Overall,
biaxial and triaxial accelerometers can detect body
movement over a wider range of physical activities than
uniaxial accelerometers and are, consequently, more sensi-
tive [8]. Compared to indirect calorimetry, biaxial acceler-
ometer measurement is a feasible and valid method in the
assessment of the energy expenditure - even in patients
with chronic respiratory failure receiving long-term oxy-
gen therapy [9]. Only triaxial accelerometers have suffi-
cient sensitivity to detect the small movements during
sitting and standing [6]. The main limitations of acceler-
ometers are cost, poor patient compliance, and low signal-
to-noise ratio from motion artifacts [2]. In addition, no
minimally- important difference has been established for
the measurement of physical activity by means of motion
sensors.
Significance
Physical activity is influenced, in part, by genes: a study
of twins showed that genetic factors explained 72 % of
the variance in activity-induced energy expenditure and
78 % of the variance in physical activity in daily life [10].
These findings suggest that genetics play a prominent
role in determining physical activity in healthy individuals.
When compared to healthy controls, COPD patients have
a marked reduction in physical activity. Those with mod-
erate to severe airflow obstruction show lower walking
time, standing time, and movement intensity during walk-
ing, as well as higher sitting time and lying time [11].
Interestingly, the clinical characteristics of patients with
COPD incompletely predict physical activity level [12]. In
a large cohort of COPD patients, significant limitations of
physical activity were present in those with Global Initia-
tive for COPD (GOLD) stages II-IV [12].
In contrast to healthy subjects, physical activity in
COPD patients is significantly related to exercise cap-
acity (such as the 6-min walking distance); however, this
relationship is not particularly strong and has limited
predictive value [13]. Patients with COPD may suffer
from comorbidities that in turn may independently have
an impact on physical activity level. Interestingly, in a
large cohort of patients with COPD, higher values of
systemic inflammation and left heart dysfunction were
found to be associated with reduced physical activity
[14]. In the same study, anemia, systemic blood pressure,
nutritional depletion and depression were not associated
with reduced physical activity levels [14].
Social conditions and health status are also related to
physical activity in patients with chronic respiratory dis-
ease. In a population-based public health survey, better
self-rated health status and quality of life in individuals
with self-reported COPD are associated with higher
levels of physical activity [15]. Most importantly, lower
physical activity is associated with a higher risk of hos-
pital admission due to COPD exacerbations, [16–18]
and is one of the most potent predictors of mortality in
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COPD, even after controlling for relevant confounding
factors [16, 18, 19].
Summary
The terms “physical activity” and “exercise capacity” ex-
press different, but related, concepts. In simple terms,
physical activity indicates what someone actually does,
while exercise capacity indicates what a person is capable
of doing. There are several techniques to assess physical
activity. Although calorimetry and, notably, DLW, are the
“gold standards” for measuring physical activity, acceler-
ometers can be considered as reliable alternative tools.
Physical activity may be significantly reduced in COPD,
but is poorly related to the clinical characteristics of the
patients. Most importantly, physical activity is reduced in
COPD patients with a history of disease exacerbations,
and is one of the most potent predictors of mortality in
these patients. Physical activity is now recognized as an
important outcome measure in pulmonary rehabilitation
of COPD and a key focus of self-management strategies.
Increasing physical activity through
pharmacotherapy in COPD (Richard Casaburi)
Key points
1. Inactivity is highly prevalent in COPD
2. Inactivity is a strong predictor of mortality in COPD
3. Activity level correlates poorly with exercise
tolerance because activity has a large behavioral
component
4. Four studies of the effect of bronchodilator therapy
on daily activity levels have been published. Results
are mixed, suggesting that bronchodilator therapy
does not increase activity level substantially.
Chronic obstructive pulmonary disease (COPD) is pri-
marily characterized by the degree of expiratory airflow
limitation it causes, but downstream consequences mag-
nify its impact on the patient. Dyspnea on exertion, re-
lated to dynamic hyperinflation leads to inactivity. This
results in atrophy of the muscles of ambulation that, in
turn, magnifies the exercise intolerance the patient experi-
ences. Developing strategies to combat inactivity has been
a major focus in COPD therapeutics in recent years [8].
A necessary prerequisite to developing therapies that
impact habitual activity is the ability to assess activity in
free-ranging individuals. Over the past decade, activity
monitors that are unobtrusive and capable of recording
over a period of many days have been developed. The
PROactive COPD Consortium has been working to per-
fect a coupling of activity monitor technology with a
fine-tuned questionnaire that will result in a single
patient-reported outcome allowing assessment of activity
in a standardized fashion [20].
Several studies have been published regarding activity
levels in COPD patients. What has been learned so far is
very informative. Activity levels are substantially reduced
in COPD patients, not only (as expected) in those with
severe disease, but in those with mild disease as well
[12, 21]. Further, in one of the most profound COPD pub-
lications in the past decade, it was shown that inactivity is
the strongest predictor of mortality [19]. Waschki et al. re-
corded activity level in a cohort of 170 COPD patients
and then followed the subjects for an average of 4 years.
About 15 % died. In comparing the survivors to the non-
survivors, the strongest independent predictor of survival
was physical activity level. Tellingly, no subject classified
as “active” in the baseline assessment died during the fol-
low up period.
These demonstrations have led to re-examination of
COPD therapeutic goals. Heretofore, improving exercise
tolerance was believed to be the path to better long-
term outcomes (including mortality). These recent stud-
ies have made us wonder whether it is higher activity
level rather than higher exercise tolerance that is the
proximate cause of better outcomes. Though exercise
tolerance is a determinant of activity level, it is not the
only determinant: learned behaviors, health beliefs, anx-
iety and mood are other determining factors [8]. It fol-
lows that interventions that improve exercise tolerance
may or may not improve activity levels.
It is worth examining the literature to see if strategies
found to improve exercise tolerance have also been
shown to improve activity levels. Table 1 lists interven-
tions shown to improve exercise tolerance in COPD.
Pulmonary rehabilitation is probably the most attractive
candidate for activity promotion. Its effect on exercise
tolerance is large [22] and it incorporates a strong
(though usually informal) behavior modification com-
ponent. Roughly a dozen published studies have exam-
ined whether a program of pulmonary rehabilitation
increases the objectively measured activity level of
COPD patients [23].
The results of these studies are mixed, with roughly
half finding significant increases in measures of activity
after rehabilitation; this is an encouraging finding. Of
the other listed interventions in Table 1, some may be
dismissed. It seems unlikely that, with current technol-
Table 1 Interventions shown to improve exercise tolerance in
COPD
• Bronchodilators
• Supplemental oxygen
• Heliox breathing
• Anabolic drugs
• Ventilatory support
• Pulmonary rehabilitation
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ogy, heliox breathing can be made practical for everyday
use during ambulation. Though anabolic drugs have
been shown to increase muscle strength, [24] to my
knowledge, no studies of the influence of anabolic drugs
on activity have been published. Apparatuses to facilitate
non-invasive ventilatory support were, until recently, too
unwieldy for routine ambulatory use. Impressive exercise
tolerance enhancement has been demonstrated in a de-
vice designed for use in conjunction with cylinder oxy-
gen and weighing one pound [25]; whether activity levels
are enhanced remains to be demonstrated.
To date, four studies have been published whose aim
was to determine whether bronchodilator therapy in-
creases activity levels of COPD patients. The results of
these studies are mixed.
 A 2010 study examined the effect of the once-daily
long-acting beta-agonist indacaterol on exercise
tolerance; activity level was a secondary outcome
[26]. Ninety COPD patients (average FEV1 = 61 %
predicted) were studied during two 3-week periods
in which they received indacaterol or placebo in
randomized blinded order. The Armband activity
monitor was worn during the last 5 days of each of
the two periods. Despite improvements in constant
work rate exercise tolerance, estimated daily energy
expenditure and daily duration of physical activity did
not differ between indacaterol and placebo periods.
 The effect of indacaterol on activity levels was
reported by a different group of investigators in a
2014 publication [27]. 129 COPD patients (average
FEV1 = 64 % predicted) were recruited to a three-
period, cross-over study (3 weeks of treatment
separated by 2-week wash-out periods) in which
they received indacaterol, matching placebo or
tiotropium. The Armband activity monitor was worn
for one week at the end of each of the 3 periods.
Compared to placebo, indacaterol administration was
associated with a statistically significant 9.8 %
increase in daily step count and a 28.8 % increase
in minutes/day of at least moderate activity.
(Results of tiotropium administration were not
reported). The authors opined that “It is difficult
to interpret the contrasting observations” of theirs
and the 2010 study.
 In the largest study to date, 457 GOLD stage 2
COPD patients (average FEV1 = 66 % predicted),
naive to maintenance bronchodilator therapy,
were randomized to 24 weeks of the once-daily
anticholinergic tiotropium or placebo [28]. The
Armband activity monitor was worn at baseline and
for one-week periods at 6 intervals over the 24 weeks
of the intervention. While physical activity levels
(step count and time spent in at least moderate
activity) were higher numerically in the tiotropium
group than in the placebo group, they were not
statistically significantly different between groups at
any time point.
 In a cross-over study involving 112 COPD patients
(average FEV1 = 57 % pred), subjects were studied
during two 3 week periods in which they received the
twice-daily anticholinergic bronchodilator, aclidinium,
or placebo in randomized blinded order [29]. The
Armband activity monitor was worn at baseline and
during the last 7 days of each of the two periods.
The authors concluded that aclidinium significantly
improves physical activity in patients with COPD,
however, a close reading suggests that the results
are not so clear-cut. Daily step count and a derived
measure of overall physical activity did not improve
significantly during aclidinium administration. The
main significant finding was that the daily duration
of at least moderate intensity physical activity
decreased in the placebo period by and average of
5.9 min and increased in the aclidinium period by
an average of 4.2 min…a modest and arguably not
clinically important effect.
These studies, taken together, might indicate that bron-
chodilators have, at most, modest effects on daily activity
levels in COPD. It might be posited that bronchodilators,
on their own, may not increase daily activity if long-
standing behavioral factors are not addressed.
Only one study, and a small one at that, has attempted
to determine whether ambulatory oxygen affects everyday
activity levels of COPD patients with severe hypoxemia
[30]. Twenty-two COPD patients (average FEV1 = 33.6 %
predicted) meeting criteria for continuous long-term oxy-
gen therapy (average resting PaO2 = 51.7 torr) and using
E-cylinders (weighing 22 pounds, towed on a cart) were
recruited. It was posited that subjects randomized to re-
ceive lightweight ambulatory oxygen supplies (compressed
gas cylinders weighing 4 pounds) would demonstrate
higher activity levels, and greater oxygen use, than those
continuing to use E-cylinders. Subjects were monitored
with an RT3 triaxial accelerometer for two-week periods
at baseline, 3 months and 6 months post-randomization.
The time course of daily activity was not impacted in the
group randomized to lightweight oxygen. Continuous
electronic monitoring of oxygen use showed that the light-
weight supplies did not improve oxygen adherence. It may
be posited that, here too, providing the ability to be more
active does not translate into higher activity levels in the
face of ingrained habits of inactivity.
Future studies might focus on combining a pharma-
cologic intervention with one focused on behavior. An
attractive design might be to determine whether bron-
chodilators (for example) enhance the effectiveness of
Ambrosino et al. Multidisciplinary Respiratory Medicine  (2015) 10:30 Page 4 of 12
rehabilitative or behavior modification interventions in
improving activity. This approach was found successful
in a somewhat analogous situation: tiotropium was
found capable of amplifying the effectiveness of a re-
habilitative exercise program in improving a measure
of exercise tolerance [31]. Given the recent demonstra-
tions of the importance of activity in determining
COPD prognosis, it seems likely that these studies will
be pursued.
Pulmonary rehabilitation in critical illness
Rationale
Emerging evidence indicates that pulmonary rehabilita-
tion is effective in the hospitalized respiratory patient,
both in preventing subsequent hospitalization and redu-
cing mortality risk.
Complex COPD with comorbidities and its impact during
acute exacerbation (Enrico Clini)
Key points
 The acute exacerbation of COPD (AECOPD) is a
very severe event during the course of the disease,
and is characterized by enhanced systemic
inflammation, increased disability, and poor
prognosis
 Comorbidities negatively impact the AECOPD
 The provision of pulmonary rehabilitation may be
beneficial for the AECOPD, especially for those with
high disease burden and multiple comorbidities
AECOPD background
Acute exacerbations (AE) of chronic obstructive pulmon-
ary disease (COPD) are events associated with a change in
the patient's baseline condition, involving worsening of
usual symptoms and requiring a change in regular medica-
tion [32]. Severe exacerbations involve a serious deterior-
ation of health status thus leading to hospitalization and
increasing overall COPD-related medical care [33].
AECOPD are characterized by quantitative changes in
severity of symptoms, rather than by the onset of unique
new symptoms. Increased coughing has been reported
by around 50 % of patients, followed increased shortness
of breath, fatigue, and sputum production [34]. In
addition, up to 45 % of patients remain in bed during
the course of the exacerbation, leading to progressive
and severe inactivity.
Although the diagnosis of the AECOPD is based on
respiratory symptoms, systemic consequences are im-
portant factors in morbidity. Frequent co-morbid condi-
tions in COPD not only contribute to the underlying
inflammation of target organs (such as the lungs, myo-
cardium, vessels, and adipose tissue) [35, 36] they also
add to fatigue and dyspnoea [37]. The frequency and
often substantial impact of co-morbid conditions make
it difficult to determine what specifically is causing the
clinical deterioration during the AECOP.
The complex COPD patient and impact of comorbid
conditions during the AECOPD
Chronic conditions are very frequently present in COPD
patients [38]. For example, in one analysis, 32 % had one
comorbid condition, and 39 % had two or more comor-
bidities [39]. In another analysis, COPD patients were
reported to have a median of nine comorbidities [40].
Cardiovascular diseases and conditions (including hyper-
tension, atherosclerotic coronary artery disease, congest-
ive heart failure, atrial fibrillation, stroke and peripheral
vascular disease) are the most common comorbid condi-
tions, followed by metabolic disorders, musculoskeletal
diseases, and mood disturbances [41].
The onset of AECOPD in complex patients with co-
morbidities is, per se, associated with increased risk for
cardiovascular events and thrombosis, which are linked
to prolonged hospital stay [42]. This association suggests
a potential role of anti-platelet therapy in this setting
[43]. Pre-existent comorbid conditions and acute, non-
cardiovascular complications (renal failure, gastrointestinal
and neurological dysfunctions) during the AECOPD con-
tribute to the risk of respiratory failure and to the 6-
month post-discharge mortality - even more than the
severity of the underlying respiratory disease [44].
Peripheral muscle dysfunction, a prominent systemic
consequence of the AECOPD, contributes to inactivity
during and after the event. The cause of this muscle dys-
function during exacerbations is multi-factorial, and un-
doubtedly varies from patient to patient [34]. These
include enhanced systemic inflammation, the use of cer-
tain medications such as oral corticosteroids, and phys-
ical inactivity [45]. Compromised energy balance during
AECOPD also contributes to muscle dysfunction in these
patients [46]. Indeed, dietary intake could be very low ac-
cording to the reported inability to eat more, following in-
creased dyspnea and fatigue. Furthermore, leptin hormone
suppressing appetite and other pro-inflammatory cyto-
kines are increased during AE, [47] which may further re-
duce appetite. Additionally, negative nitrogen balance
during the AECOPD [48] results in a catabolic state. Fi-
nally, in patients developing respiratory failure, hypoxia
and even hypercapnia also add to the muscle dysfunction.
Sustained reduction of arterial oxygen leads to an activa-
tion of pro-inflammatory cytokines [49] and increased
damage following oxidative stress [50]. When it occurs,
acute hypercapnia-induced intracellular acidosis has a
negative influence on cell metabolism and respiratory and
limb muscle contractility [51].
All these factors rapidly lead to symptoms and disabil-
ity, which may persist up to 1 month after discharge
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[45]. The relationship between daily physical activity
level on one hand and risk for hospitalization and mor-
tality on the other hand has been documented [19, 52].
Role of rehabilitation during AE in the complex COPD
patient
The profound systemic effects of AECOPD point to the
need for a comprehensive treatment, which may include
systemic anti-inflammatory drugs, reduction of ventila-
tory requirements and work of breathing, adequate oxy-
gen supply and nutritional support, and treatment of
complications. While these aspects of care are generally
included in the acute hospital setting, rehabilitation –
until recently - has frequently been overlooked as a crit-
ical treatment modality. In a cohort of around 70,000
hospitalized COPD patients, Lindenauer and coworkers
[53] reported that usual pharmacological means of care
are frequently used during the course of AE, but delivery
of rehabilitation is never mentioned among therapies.
Only recently, the additional approach of physical
therapies in the context of acute care has been applied to
the COPD patient admitted with an AECOPD. Troosters
and co-workers have reported the feasibility and beneficial
effects of peripheral muscle training during hospitalized
COPD patients undergoing severe exacerbation [54].
Compared with untreated controls, incremental resistance
training over a 1-week period counteracted the deleterious
effects of the exacerbation on quadriceps muscle force.
Even if that study cannot prove that muscle catabolism
can be counterbalanced by a short period of resistance
training, it does show that quadriceps resistance training
during an AE of COPD can assist patients in maintain-
ing their function during and after the stay in hospital.
As a practical consequence from this trial, it may ap-
pear that in-hospital rehabilitation during AECOPD
(beyond the usual medical therapy) is potentially rele-
vant as a non-pharmacological therapy at the earliest
onset of disability [55].
Other forms of physical therapy have been utilized in
very severe COPD patients recovering from AECOPD. A
step-by-step muscle training intervention in a high-
dependency respiratory care unit was given to spontan-
eously breathing COPD patients just weaned from
mechanical ventilation [56]. In that trial, the application
of incremental training improved both functional cap-
acity and physical independence.
Finally, passive training of specific locomotor muscle
groups by means of low-volt electrical stimulation (ES)
may also be useful in very deconditioned or bed-bound
patients recovering from AECOPD, including those with
marked peripheral muscle hypotonia and atrophy, and
those just weaned from mechanical ventilation [57]. In
particular, the early application of ES in COPD patients
recovering from a severe AECOPD may result in
significantly improved limb muscle strength and in en-
hanced clinical outcomes such a the lower number of
days needed to transfer themselves from bed to chair.
Despite these preliminary data, there is still no consen-
sus on how to apply physiotherapy in patients admitted
with AECOPD and how disease complexity and comor-
bidities may impact on delivery and effectiveness of the
rehabilitation process. Data from outpatient studies indi-
cates that pulmonary rehabilitation provides substantial
benefits in severe and disabled, complex COPD, [58]
even in those with multiple comorbidities. This provides
some rationale for its use in patients hospitalized for the ex-
acerbation. Thus, complexity and multimorbidity, per se, do
not preclude physical therapy to these patients.
Collaborative self-management in COPD: a
double-edged sword? (Linda Nici)
Self-management is an important part of the chronic
care model of disease management, [59] which also in-
cludes clinical information systems, delivery system re-
design, decision support, health care organization, and
community resources. Self-management provides the
knowledge and skills that are necessary to achieve optimal
outcome [60]. Self management enhances behavior change
and promotes self-efficacy. Medical literature on self-
management implies collaborative self-management, in
which the health care professionals and patient work to-
gether on strengthening and supporting self-care to
minimize the impact of chronic illness [61, 62].
COPD, self-management centers on an action plan for
early recognition and prompt treatment of the respiratory
exacerbation. Earlier treatment of the COPD exacerbation
reduces morbidity risk and decrease health care utilization
[63, 64]. Other examples of self-management include in-
creasing regular exercise and physical activity, smoking
cessation, medication compliance, and proper coping
skills.
An early study of self-management [65] demonstrated
that an outpatient intervention, which centered on a
customized action plan for the COPD exacerbation,
resulted in a 40 % decrease in hospital admissions for ex-
acerbations. This beneficial effect on health care utilization
lasted for two years.
In 2010, Rice and colleagues [66] reported on a multi-
center, disease management (self-management) interven-
tion in 743 US veterans with COPD who were at high risk
for hospitalization or emergency department visits. Pa-
tients were provided with an individualized, written action
plan that included prescriptions for prednisone and antibi-
otics, instructions on when to begin them, and informa-
tion for contacting a case manager. This concise self
management treatment substantially reduced COPD hos-
pitalizations and emergency department visits by 41 %.
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These promising results were tempered by the findings
from a concurrent study by Fan and colleagues [67] (pub-
lished in 2012), which involved a similar population. COPD
patients at risk for hospitalization were randomized to
usual care versus a self-management program delivered by
allied health professionals. This program was even more
comprehensive than in the Rice study, and included mul-
tiple sessions and frequent follow-up with a case manager.
Time to first COPD hospitalization was the primary out-
come. Quite surprisingly, this study had completely unex-
pected results: it was terminated prematurely due to a
mortality signal in the treatment group (hazard ratio of
death of 3.00, p. = 0.003)! Furthermore, there was no ob-
served health care utilization benefit from the self-
management intervention. The reasons underlying the in-
creased mortality remain unknown to this day.
Several subsequent studies of self-management, while
not demonstrating increased mortality, failed to show ben-
efits in health care utilization or other important outcomes
[68, 69]. The inconsistent results from these five recent tri-
als mandate that self-management in COPD must be re-
examined and re-structured. A cursory review of the (nega-
tive) Fan study trial suggests that the intervention was de-
livered according to protocol in that 87 % of treatment
patients completed all sessions and case managers com-
pleted 89 % of follow-up contact. Strikingly, however, pa-
tients did not report to the health care provider if they had
exacerbations even though they were explicitly instructed
to do so (of 600 self-reported exacerbations calls were
made only 27 times). In addition, the time to initiation
of steroid or antibiotics was excessively long and not
different between the two groups. This indicates that the
self-management process was ineffective.
An explanation behind this ineffectiveness is that suc-
cessful self management may be difficult to achieve in
COPD patients. Support for this idea comes from a
post-hoc analysis in the Bucknall study in which only
about 40 % of COPD patients were able to successfully
self-manage. This observation was supported by another
analysis which showed very similar results. In only 40 %
of exacerbations did patients adhere to the action plan.
We need to increase this percentage to achieve effective
outcomes after self-management.
How do we address the increased mortality observed
in the Fan trial? Hospitalized COPD patients have a high
risk for mortality; these fragile individuals may not only
need an early intervention with antibiotics and steroids
(per action plan), but also timely assessment by experi-
enced respirologists. The heavy reliance on a case man-
ager may have delayed this assessment. Additionally,
assuming increased patient self efficacy results from this
treatment (which the primary goal) this, in turn, may
have had the negative consequence of over-confidence
and delay in timely therapy.
The most recent Cochrane review [70] provides some
perspective on the discordant self-management results.
With the exception of the negative Fan study, this sys-
tematic review tells us that self-management is indeed
successful, with benefit in the areas of respiratory-
related hospital admissions, all-cause hospital admis-
sions, and mortality. Successful self-management in
COPD rests on two pillars: education and behavior modi-
fication. We must determine the individual patient’s learn-
ing style, and then adapt our intervention accordingly.
Furthermore, we must identify those who would poten-
tially be harmed by a generic application of the self-
management intervention. In this setting, “one size does
not fit all.”
Pulmonary rehabilitation in critical illness:
neuromuscular electrical stimulation: rationale
and effectiveness (Carolyn Rochester)
Key points:
 ICU-acquired muscle weakness (critical illness
neuromyopathy) is a common problem
 Early mobilization interventions have the potential
both to prevent, and hasten recovery from
ICU-acquired muscle weakness
 Multiple barriers in implementing physical therapy
and early mobilization in the intensive care units
exist
 Neuromuscular electrical stimulation (NMES) of
skeletal muscle is an alternate rehabilitation
technique suitable for use in the ICU for critically ill
patients.
 Preliminary data suggest that NMES holds promise
across several outcome areas in critically ill patients
Approximately 13 to 20 million people worldwide re-
quire life support in intensive care units annually for
various forms of critical illness [71]. Muscle weakness is
a common sequel of critical illness. Overall, approxi-
mately 25 % of patients who require prolonged mechan-
ical ventilation in the ICU develop generalized and
persistent muscle weakness; approximately 1 million pa-
tients develop the syndrome of ICU-acquired weakness
(critical illness neuromyopathy) annually [72–74]. Risk
factors include sepsis, multiple organ failure, prolonged
mechanical ventilation, use of neuromuscular blockade
medications, poor glycemic control and hypoalbumin-
emia [74, 75]. Immobility also plays an important role in
the development of weakness in the ICU. Muscle mass
decreases by an estimated 1.5-2 % per day of bed rest;
the muscles of the lower limbs and torso are most af-
fected [76, 77]. In one study, muscle strength decreased
by 3-11 % for each day of bed rest in the ICU over 2-
years of follow-up [78]. Alterations in anabolic-catabolic
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signaling contribute to this loss of muscle mass. ICU-
acquired weakness often lasts for months to years fol-
lowing hospitalization, and is associated with increased
duration of mechanical ventilation, [79, 80] increased
hospital and ICU length of stay, [73] prolonged physical
symptoms and functional disability, [81, 82] impaired
quality of life [81] and increased mortality [83].
Early mobilization interventions have the potential
both to prevent, and hasten recovery from ICU-acquired
muscle weakness. Indeed, several recent clinical trials
demonstrate that early mobilization of carefully-selected
critically ill patients is feasible and safe [84–86] and im-
proves several short-term patient outcomes, [87–89] in-
cluding exercise tolerance and physical function, [84],
fewer days of delirium, [84] fewer ventilator-dependent
days [87] and reduced hospital/ICU length of stay [90].
Different aspects of rehabilitation are needed across the
continuum of the patient’s illness. Individualized goal-
oriented treatment plans should be developed and moni-
tored for each patient. Multidisciplinary rehabilitation
teams and protocols are desirable. Consensus recom-
mendations on safety criteria for active mobilization of
critically ill adults receiving mechanical ventilation have
been published recently [91]. However, implementation
of early mobilization in the ICU requires a major para-
digm shift, [92, 93] given that bed rest was historically
thought to be beneficial for critically ill patients.
Provision of physical rehabilitation to critically ill patients is
effort-intensive and requires resources, including skilled
multidisciplinary personnel, specialized equipment and
time, and can be associated with considerable costs
[93, 94]. Despite knowledge of its benefits, multiple barriers
to implementation exist [95–97]. Patient-related barriers in-
clude sedation, pain, delirium, cognitive impairment, need
for procedures, the presence of catheters and other devices
(such as chest tubes, pacemakers etc.), and need for proce-
dures. Staff-related barriers include time commitment, staff
concerns for patient safety and personal injury risk as well
as work-related stress [97]. As a result of these issues, early
mobilization in the ICU remains underutilized [98, 99].
Neuromuscular electrical stimulation (NMES) of skel-
etal muscle [100] is an alternate rehabilitation technique
suitable for use in the ICU for critically ill patients. It is
a method of activating skeletal muscle fibers without the
requirement for conventional physical exercise. Electrical
impulses are delivered via surface electrodes applied on
the skin over muscles targeted for activation and muscle
contraction is elicited. A protocol for NMES must be
established that includes electrical pulse frequency (Hz),
pulse duration (Sec), duty cycle (contraction time/total
time: defined usually as the duration of trains of pulses
relative to the interval between trains of pulses), stimu-
lus amplitude (mA), and general training parameters
such as the number of sessions per week, duration of
session and total duration of training [100]. One can stimu-
late single muscles or multiple muscles simultaneously.
NMES can be provided alone, or in combination with other
exercise such as cycling or walking, wherein it is often
termed “functional electrical stimulation (FES)” [101].
NMES is a potentially desirable method of muscle re-
habilitation for critically ill patients for several reasons.
It requires fewer personnel than conventional physical
rehabilitation, can be delivered even to immobilized, se-
dated or delirious patients, does not interfere with other
devices (such as central venous catheters or chest tubes)
and poses minimal cardio-ventilatory demand [102, 103].
It can improve or prevent disuse atrophy in healthy
adults, [104] at least in part by promoting maintenance
of protein synthesis [105]. NMES has been used for
many years in the rehabilitation of people recovering
from limb injury or orthopedic surgery. It also im-
proves limb muscle strength and exercise capacity of
people with chronic illnesses such as chronic obstruct-
ive pulmonary disease, congestive heart failure and lung
cancer [106].
In recent years, several studies have investigated the
efficacy of NMES in preventing and/or assisting recovery
from muscle weakness among critically ill patients. Two
randomized, clinical trials [107, 108] and several obser-
vational and randomized intervention studies have inves-
tigated the effect of NMES on muscle mass in groups of
patients with mixed forms of critical illness [109–111].
In one of the RCT, 8 days of NMES to the quadriceps
and peroneus longus muscles begun within 48 h of ICU
admission attenuated the decline in muscle cross sec-
tional diameter (assessed by ultrasound) over the course
of the study as compared with the control group; [107]
noted benefits were more prominent in one leg than the
other. In the other RCT, NMES led to increased quadriceps
thickness (compared with sham stimulation) for a group of
patients who had the intervention begun more than two
weeks after ICU admission, but not for persons for whom
NMES was begun within one week of ICU admission [108].
In the uncontrolled studies, NMES prevented atrophy or
improved muscle mass in some, [109, 110] but not all,
[111] studies. A study of NMES among patients with septic
shock also failed to demonstrate any benefit of NMES on
muscle mass [112]. Four trials, three of which involved pa-
tients with mixed forms of critical illness [113–115] and
one among bed bound patients with COPD with respira-
tory failure requiring mechanical ventilation [116] have
demonstrated improvement in lower and/or upper extrem-
ity muscle strength following NMES treatment applied in
the ICU. Muscle strength was assessed in these studies by
the Medical Research Council Muscle Strength score [117].
In the RCT by Routsi, [113] fewer patients in the NMES
group developed critical illness neuromyopathy and these
patients required a shorter duration of mechanical
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ventilation as compared with the control group. One recent
RCT evaluated the impact of NMES on a broader range of
outcomes at the times of ICU awakening, ICU discharge
and hospital discharge among 34 critically ill patients [118].
Maximal walking distance was greater and there was a
trend towards improvement in lower extremity muscle
strength assessed by MRC score at hospital discharge in the
NMES group. No differences were demonstrated be-
tween the NMES and control groups in other measures
of muscle strength, overall body MRC score, functional
status, activities of daily living, duration of mechanical
ventilation, hospital or ICU length of stay, disposition
location of survivors, ICU readmissions, ICU or hos-
pital mortality, or hospital costs [118]. A recent case
matched control study comparing FES with cycling to
usual ICU care demonstrated that FES led to shorter
duration of delirium, shorter time to ability of the pa-
tient to march in place, and improved Physical Func-
tion in Intensive Care test scores [101]. There were no
differences in time to stand, time to first or independ-
ent ambulation, ICU or hospital length of stay, dis-
charge destination or mortality. Thus, at present, it is
not yet clear whether NMES provided during critical
illness improves patients’ long-term outcomes.
In conclusion, NMES for critically ill patients is an ap-
pealing intervention with promise for beneficial patient
outcomes. However, most trials conducted to date are
small and heterogeneous patient populations, trial design
and study methodologies preclude formulation of defini-
tive conclusions regarding efficacy of NMES applied in
the ICU setting. Further work is needed to identify the
optimal rehabilitation methods for persons with varying
forms of critical illness. With regard to NMES, further
research is needed to identify the optimal stimulation
protocols and parameters, identify the patients most
likely to benefit, assess feasibility, safety, possible sys-
temic effects, cost-effectiveness, its role in combination
with conventional exercise rehabilitation, its impact on
clinically relevant outcomes such as daily function and
quality of life if begun during critical illness and contin-
ued across post-ICU healthcare and home venues.
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